Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 1

Conditions

Lung Neoplasms 10Small Cell Lung Carcinoma 9Mesothelioma, Malignant 7Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Sarcoma 3Thymoma 2Ovarian Neoplasms 2Neoplasms 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Glioma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymic epithelial tumor 1Stomach Neoplasms 1Sezary Syndrome 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma × Doxorubicin × Thoracic × Clear all
NCT03034850 2017-01-27

Thrombin Generation and Platelet Activation in CRS/HIPEC

Ziekenhuis Oost-Limburg

Completed
27 enrolled
GynecologicOther solid neoplasmThoracic

Mesothelioma, Peritoneal Neoplasms, Pseudomyxoma Peritonei

NCT00634205 2015-02-12

Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma

European Lung Cancer Working Party

Phase 2 Completed
45 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡